万孚生物(300482) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥696,605,661.68, representing a 26.27% increase compared to ¥551,691,594.07 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2021 was ¥155,422,449.02, up 58.84% from ¥97,845,765.19 in the previous year[8]. - The net profit after deducting non-recurring gains and losses was ¥141,413,760.51, an increase of 48.61% from ¥95,159,770.28 year-on-year[8]. - The basic earnings per share for Q1 2021 was ¥0.46, a 58.62% increase from ¥0.29 in the same period last year[8]. - The company achieved operating revenue of 696.61 million yuan in Q1 2021, a year-on-year increase of 26.27%[26]. - Net profit attributable to shareholders reached 155.42 million yuan, up 58.84% compared to the same period last year[26]. - The net profit for the current period was ¥152,445,830.45, compared to ¥97,274,590.66 in the previous period, indicating an increase of approximately 56.7%[68]. - The company reported a total comprehensive income of ¥152,985,548.62, compared to ¥98,461,254.86 in the previous period, an increase of about 55.3%[72]. - The net profit for the current period is 168,236,158.06, compared to 106,864,138.04 in the previous period, representing a growth of approximately 57.3%[76]. - The total comprehensive income for the current period is 168,236,158.06, up from 106,864,138.04, indicating a significant increase of about 57.3%[79]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,459,966,143.42, reflecting a 3.57% increase from ¥4,306,097,245.20 at the end of the previous year[8]. - Total assets increased to ¥4,459,966,143.42, up from ¥4,306,097,245.20, representing a growth of approximately 3.57%[55]. - Non-current assets totaled ¥2,081,906,288.22, compared to ¥2,035,803,309.51, indicating an increase of about 2.27%[55]. - Current liabilities decreased to ¥732,265,983.42 from ¥793,449,464.58, a reduction of approximately 7.73%[52]. - Total liabilities amounted to ¥1,296,573,841.15, slightly down from ¥1,312,467,101.44, reflecting a decrease of about 1.21%[52]. - Owner's equity rose to ¥3,163,392,302.27, compared to ¥2,993,630,143.76, marking an increase of approximately 5.68%[55]. - The total liabilities decreased slightly to ¥1,181,776,830.64 from ¥1,200,059,369.52, a reduction of approximately 1.5%[62]. - Owner's equity increased to ¥3,086,947,256.02 from ¥2,901,934,487.96, reflecting a growth of about 6.4%[62]. - The total liabilities rose from 1,312,467,101.44 to 1,324,283,978.40, which is an increase of approximately 0.13%[95]. Cash Flow - The net cash flow from operating activities for Q1 2021 was ¥20,347,935.11, a significant decrease of 95.83% compared to ¥488,250,910.42 in the same period last year[8]. - Cash inflow from operating activities totaled 619,354,290.97, down from 971,609,342.31, reflecting a decrease of approximately 36.2%[84]. - The net cash flow from operating activities is 20,347,935.11, a decline from 488,250,910.42 in the previous period, showing a decrease of about 95.8%[84]. - Cash inflow from investment activities is 1,723,695,815.97, compared to 1,209,043,160.65, marking an increase of approximately 42.5%[84]. - The net cash flow from investment activities is -441,533,853.84, an improvement from -745,872,167.67, indicating a reduction in losses of about 40.7%[84]. - The cash and cash equivalents at the end of the period stand at 942,547,918.21, compared to 709,838,465.24, representing an increase of approximately 32.7%[86]. - The company reported a decrease in cash received from sales of goods and services, totaling 578,912,056.61, down from 960,277,139.22, a decline of about 39.6%[80]. - The total operating expenses for the current period are 599,006,355.86, compared to 483,358,431.89, reflecting an increase of approximately 23.9%[84]. - The company has reported a significant increase in employee compensation payments, totaling 245,572,672.70, compared to 158,992,284.87, which is an increase of about 54.3%[84]. - The cash flow from operating activities was not detailed but is critical for assessing the company's operational efficiency[90]. Investments and R&D - Research and development expenses increased by 40.25% to 826.37 million yuan, reflecting a rise in R&D investment[25]. - The company has committed to investing a total of approximately ¥129.33 million in various projects, with a significant portion allocated to the chemical luminescence technology platform[33]. - The company reported a 100% utilization of funds from the non-public offering project, amounting to approximately ¥12.70 million[33]. - The company continues to focus on investment activities, with cash inflows totaling 1,642,276,450.29, up from 1,161,180,067.69 in the previous period, reflecting a growth of approximately 41.4%[90]. Market Position and Strategy - The company has obtained CE certification and emergency approval for its COVID-19 antigen test kits, expanding its market presence in over 100 countries[26]. - The company is the only domestic entity with registration certificates for both COVID-19 antigen and antibody tests, enhancing its competitive edge[26]. - The company is focusing on a dual strategy of "regular business and COVID-19 business" to drive growth in both domestic and international markets[26]. - The increase in sales expenses to ¥173,832,707.07 from ¥146,417,106.98 reflects the company's strategy to enhance market presence and customer engagement[65]. Compliance and Governance - The company has not reported any non-compliance issues regarding external guarantees during the reporting period[39]. - The company has engaged in communication with institutional investors regarding its operational status, indicating transparency and investor relations efforts[42]. - The first quarter report for 2021 has not been audited[103].